Efficacy and safety of zanubrutinib combination therapy and monotherapy maintenance in patients with follicular lymphoma: A retrospective single-center analysis
Retrospective analysis shows zanubrutinib's efficacy in follicular lymphoma, suggesting further study of combination therapy or monotherapy maintenance.
Key Points
Zanubrutinib led to a complete response in 37.5% of patients with follicular lymphoma and an overall response rate of 87.5%.
In the combination therapy group, progression-free survival has yet to be reached in an average follow-up of 7 months post-treatment.
Retrospective analysis assessed 15 patients with follicular lymphoma treated at Fujian Medical University Union Hospital between May 2023 and July 2025.
These results indicate zanubrutinib may support further research in broader treatment applications for follicular lymphoma.